

SAFETY DATA SHEET

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name CARFLEXIN INJECTION
Synonyms CARPROFELICAN INJECTION

1.2 Uses and uses advised against

Uses CAT TREATMENT • DOG TREATMENT • HORSE TREATMENT • PAIN RELIEF • VETERINARY

APPLICATIONS

1.3 Details of the supplier of the product

Supplier name DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY LTD

Address 2 Cal Close, Somersby, NSW, 2250, AUSTRALIA

Telephone 1300 015 825; (02) 4372 1661

 Fax
 (02) 4372 1668

 Email
 info.au@dechra.com

 Website
 http://www.dechra.com.au/

1.4 Emergency telephone numbers

Emergency 13 11 26 (Poisons Information Centre)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

NOT CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

2.2 GHS Label elements

No signal word, pictograms, hazard or precautionary statements have been allocated.

2.3 Other hazards

No information provided.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content (w/v)
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	100%

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to

stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

Inhalation If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

Skin If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

Ingestion For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If

swallowed, do not induce vomiting. Rinse mouth with water provided person is conscious.

Page 1 of 6

ChemAlert.

SDS Date: 23 Jan 2023

PRODUCT NAME CARFLEXIN INJECTION

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve toxic gases if strongly heated.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store between 2°C and 8°C, in a cool, dry, well marked area, removed from foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children.

Page 2 of 6

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.



SDS Date: 23 Jan 2023

PRODUCT NAME **CARFLEXIN INJECTION**

PPE

When using large quantities or where heavy contamination is likely, wear splash-proof goggles. Eye / Face

Hands Wear latex gloves.

Body In a laboratory situation, wear a laboratory coat. Respiratory Not required under normal conditions of use.



9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

CLEAR BROWNISH-YELLOW LIQUID **Appearance**

Odour SLIGHT ODOUR NON FLAMMABLE **Flammability** NOT RELEVANT Flash point **NOT AVAILABLE Boiling point Melting point NOT AVAILABLE NOT AVAILABLE Evaporation rate**

5.5 to 6.5 pН NOT AVAILABLE Vapour density Relative density 1.05 to 1.09 Solubility (water) **NOT AVAILABLE** Vapour pressure **NOT AVAILABLE** Upper explosion limit NOT RELEVANT Lower explosion limit NOT RELEVANT Partition coefficient NOT AVAILABLE Autoignition temperature NOT AVAILABLE Decomposition temperature **NOT AVAILABLE** Viscosity NOT AVAILABLE **Explosive properties** NOT AVAILABLE Oxidising properties NOT AVAILABLE

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Odour threshold

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Hazardous polymerisation is not expected to occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources. Avoid freezing and exposure to light.

NOT AVAILABLE

10.5 Incompatible materials

Compatible with most commonly used materials.

10.6 Hazardous decomposition products

May evolve toxic gases if heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin **Acute toxicity**

Page 3 of 6

ChemAlert.

SDS Date: 23 Jan 2023

PRODUCT NAME CARFLEXIN INJECTION

contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

Skin Exposure considered unlikely. Due to product form, adverse health effects via skin contact are not

anticipated. However, accidental injection into the skin (needle stick injury) may result in a local injection site

eaction.

Eye Exposure to contents is considered unlikely. Due to product form and nature of use, the potential for

exposure is reduced. However, if unit is damaged contact may result in irritation and lacrimation.

Sensitisation Not classified as causing skin or respiratory sensitisation.

MutagenicityNot classified as a mutagen.CarcinogenicityNot classified as a carcinogen.ReproductiveNot classified as a reproductive toxin.

STOT - single exposure

Not classified as causing organ damage from single exposure. Due to the product form, exposure to contents is not anticipated. However, high level exposure may result in respiratory irritation, drowsiness, dizziness,

nausea and headache

STOT - repeated

exposure

Not classified as causing organ damage from repeated exposure.

Aspiration Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No information provided.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal For small quantities, collect and place in sealable containers. Dispose of, as with other clinical waste, by high

temperature incineration (recommended > 1100°C). Burial to landfill may be acceptable, but only at an

approved and licensed waste disposal site.

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE, IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

Page 4 of 6

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.



SDS Date: 23 Jan 2023

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Poison schedule Classified as a Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

APVMA Numbers 92024

Classifications Safe Work Australia criteria is based on the Globally Harmonised System (GHS) of Classification and

Labelling of Chemicals (GHS Revision 7).

Inventory listings AUSTRALIA: AllC (Australian Inventory of Industrial Chemicals)

All components are listed on AIIC, or are exempt.

NEW ZEALAND: NZIoC (New Zealand Inventory of Chemicals)
All components are listed on the NZIoC inventory, or are exempt.
UNITED STATES: TSCA (US Toxic Substances Control Act)
All components are listed on the TSCA inventory, or are exempt.

16. OTHER INFORMATION

Additional information

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbreviations	ACGIH	American Conference of Governmental Industrial Hygienists
Appreviations	ACGILI	Alliencan Conference of Governmental industrial rivulentsis

CAS # Chemical Abstract Service number - used to uniquely identify chemical compounds

CNS Central Nervous System

EC No. EC No - European Community Number

EMS Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous

Goods)

GHS Globally Harmonized System

GTEPG Group Text Emergency Procedure Guide
IARC International Agency for Research on Cancer

LC50 Lethal Concentration, 50% / Median Lethal Concentration

LD50 Lethal Dose, 50% / Median Lethal Dose

mg/m³ Milligrams per Cubic Metre
OEL Occupational Exposure Limit

pH relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly

alkaline).

ppm Parts Per Million

STEL Short-Term Exposure Limit

STOT-RE Specific target organ toxicity (repeated exposure)
STOT-SE Specific target organ toxicity (single exposure)

SUSMP Standard for the Uniform Scheduling of Medicines and Poisons

SWA Safe Work Australia
TLV Threshold Limit Value
TWA Time Weighted Average

ChemAlert.

SDS Date: 23 Jan 2023

PRODUCT NAME CARFLEXIN INJECTION

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711

Fax: +61 8 9322 1794 Email: info@rmt.com.au Web: www.rmtglobal.com

[End of SDS]



SDS Date: 23 Jan 2023